The Latest News.

- Advertisment -

Chinese Patent Granted for CytoMed Therapeutics’ iPSC-Based Technology for Cancer Treatment

- Advertisement -

Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-Based Technology

SINGAPORE, Sept. 25, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based biopharmaceutical company, has announced that its licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

  • The iPSC-based technology developed by CytoMed has been granted a patent in China, further expanding the company’s current patent portfolio.
  • CytoMed’s iPSC-derived γδ NKT cells may potentially become an “off-the-shelf” cell therapy for a wide range of cancers.
  • The patent covers the technology to derive synthetic γδ NKT cells for the treatment of various types of cancers.
  • Expanding Patent Portfolio

    CytoMed is thrilled to strengthen its existing suite of patents with the grant of a patent for its iPSC-based technology in China. This novel technology has also been granted a patent in Japan, where the iPSC technology was pioneered in 2006. With these patents, the company’s current patent portfolio now spans three countries, including the US and China.

    Potential Breakthrough in Cancer Treatment

    CytoMed’s iPSC-based technology allows for the generation of γδ NKT cells, a novel type of synthetic hybrid immune cells. These cells express cancer recognition receptors of both γδ T cells and natural killer (NK) cells, enabling them to recognize a wide range of cancers without genetic modification or the use of viral vectors. As an allogeneic cell source, these iPSC-derived γδ NKT cells have the potential to become an “off-the-shelf” cell therapy applicable to a large pool of patients.

    - Advertisement -

    Promising Preclinical Development

    The recently granted patent titled “Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells” covers the technologies to derive synthetic γδ NKT cells for the treatment of various types of cancers, including hematological malignancies and solid tumors. This asset is currently under preclinical development, bringing hope for improved cancer treatment options in the future.

    For more information about CytoMed Therapeutics Limited and their innovative cell-based immunotherapies, please visit

    Source Credit

    NewsTechnology NewsChinese Patent Granted for CytoMed Therapeutics’ iPSC-Based Technology for Cancer Treatment
    Delia Reynolds
    Delia Reynolds
    Delia Reynolds is a highly-regarded tech news author with an uncanny ability to captivate readers through engaging, concise, and insightful articles. With a passion for innovation, Delia meticulously dissects the latest developments in technology, leaving no stone unturned in the quest for accurate and comprehensive news coverage.

    Disclaimer: We want to be clear that the information on, including news, articles, reviews, and opinions, is intended for reading and knowledge purposes only. While we strive to provide accurate and up-to-date information, opinion and news, we cannot guarantee the completeness, accuracy, reliability, suitability, or availability of any information. Read more

    Follow us on
    Google News
    - Advertisment -